Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089140 | 0.80 | CHRNB2 (0.67) | CHRNB2CHRNA4LMNACHRNA7GRM2 | |
| SCHEMBL6227025 | 0.79 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA7CYP2A6CYP1A2 | |
| SCHEMBL27258621 | 0.79 | CHRNB2 (0.59) | CHRNB2CHRNA4LMNACHRNA7GRM2 | |
| SCHEMBL27587590 | 0.77 | LOXL2 (0.43) | LMNACYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL22938933 | 0.76 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNA7GRM2CYP2A6 | |
| SCHEMBL12873577 | 0.76 | CHRNB2 (0.56) | CHRNB2CHRNA4LMNACHRNA7GRM2 | |
| SCHEMBL19750347 | 0.76 | CHRNB2 (0.56) | CHRNB2CHRNA4LMNACHRNA7GRM2 | |
| SCHEMBL10028665 | 0.75 | CHRNB2 (0.85) | CHRNB2CHRNA4LMNACHRNA7CYP1A2 | |
| SCHEMBL30632262 | 0.75 | CHRNB2 (1.00) | CHRNB2CHRNA4LMNACHRNA7CYP2A6 | |
| SCHEMBL3460939 | 0.75 | CHRNB2 (1.00) | CHRNB2CHRNA4LMNACHRNA7CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655247-A | Enhancing T cell function and treating T cell dysfunction disorders with a combination of a LSD inhibitor and a PD1 binding antagonist | 艾比克斯治疗私人有限公司 | 2020-09-11 | — | — | CN | claimed |
| CN-103396398-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2013-11-20 | — | — | CN | claimed |
| CN-101495464-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | CN | claimed |
| CN-114984229-A | Treatment of addiction and impulse control disorders using PDE7 inhibitors | 奥默罗斯公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112168972-A | Treatment of addiction and impulse control disorders using PDE7 inhibitors | 奥默罗斯公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-111808135-A | Functionally modified oligonucleotides and subunits thereof | 萨勒普塔医疗公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-111655247-A | Enhancing T cell function and treating T cell dysfunction disorders with a combination of a LSD inhibitor and a PD1 binding antagonist | 艾比克斯治疗私人有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-110770221-A | Methods for improving memory and cognition and for treating memory and cognitive disorders | 卡维昂公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-101495464-B | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2014-03-05 | — | — | CN | disclosed |
| CN-103396398-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2013-11-20 | — | — | CN | disclosed |
| CN-101495464-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | CN | disclosed |